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Background: Centrosomes function primarily as microtubule-organizing centres and play a crucial role during
mitosis by organizing the bipolar spindle. In addition to this function, centrosomes act as reaction centers where
numerous key regulators meet to control cell cycle progression. One of these factors involved in genome stability,
the checkpoint kinase CHK2, was shown to localize at centrosomes throughout the cell cycle.
Results: Here, we show that CHK2 only localizes to centrosomes during mitosis. Using wild-type and CHK2−/−
HCT116 human colon cancer cells and human osteosarcoma U2OS cells depleted for CHK2 with small hairpin RNAs
we show that several CHK2 antibodies are non-specific and cross-react with an unknown centrosomal protein(s) by
immunofluorescence. To characterize the localization of CHK2, we generated cells expressing inducible GFP-CHK2
and Flag-CHK2 fusion proteins. We show that CHK2 localizes to the nucleus in interphase cells but that a fraction of
CHK2 associates with the centrosomes in a Polo-like kinase 1-dependent manner during mitosis, from early mitotic
stages until cytokinesis.
Conclusion: Our findings demonstrate that a subpopulation of CHK2 localizes at the centrosomes in mitotic cells
but not in interphase. These results are consistent with previous reports supporting a role for CHK2 in the bipolar
spindle formation and the timely progression of mitosis.
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The serine/threonine checkpoint kinases CHK1 and
CHK2 are core components of the cell response to
genotoxic stresses [1-3]. In response to DNA damage,
CHK1 and CHK2 are activated by Rad3-related (ATR)
and ataxia-telangiectasia mutated (ATM) protein kinases
respectively, targeting many downstream substrates that
coordinate cell cycle checkpoint activation, DNA repair
and apoptosis [4,5]. Interestingly, recent studies have
highlighted roles for CHK1 and CHK2 during normal
cell cycle regulation in the absence of DNA damage.
CHK1 has been reported to play a role in unperturbed S
phase and in delaying the entry of cells into mitosis
[6-10]. CHK1 has also been shown to be required for
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distribution, and reproduction in any mediumfunction [11-14]. Recently, a role for CHK2 in the as-
sembly of the bipolar mitotic spindle and normal mitosis
progression has been reported [15]. This DNA-damage
-independent function of CHK2 is mediated by the
phosphorylation of the tumor suppressor BRCA1 on Ser
988, and is required to maintain chromosomal stability
in the HCT116 human colorectal tumor cell line [15].
Centrosomes function primarily as microtubule-
organizing centres and play a crucial role in the forma-
tion of bipolar spindles and chromosomal segregation
during mitosis [16,17]. In addition, increasing evidence
suggests that centrosomes also play roles in regulating
various cell signalling pathways including cell cycle regu-
lation and the DNA damage response [17-19]. Numer-
ous cell cycle regulatory molecules have been identified
at the centrosomes which are though to function as inte-
gration sites of positive and negative pathways to regu-
late cell cycle progression [17,18,20-25]. A growing
number of components of the DNA damage response
network, including p53, ATM, ATR, CHK1, CHK2, Rad
51, BRCA1 and BRCA2 have also been localized at thetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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DNA damage response [8,9,26-35]. At the G2/M bound-
ary, the molecular events that initiate entry into mitosis
occur at the centrosomes where the activation of the mi-
totic kinase CDK1-cyclinB is initiated [36-39]. Interest-
ingly, several studies report that a subpopulation of CHK1
localizes to the interphase centrosomes to regulate the
entry of cell into mitosis by inhibiting centrosomal CDK1-
cycline B activation [8-10].
Although CHK2 is mainly nuclear in somatic cells, sev-
eral reports document the presence of a subpopulation of
CHK2 at centrosomes. Strikingly, in embryonic stem (ES)
cells, CHK2 has been shown to localize exclusively at
the centrosomes and studies performed in Drosophila
melanogaster embryos suggest that DmCHK2 localizes at
the centrosomes to disrupt spindle assembly and chromo-
some segregation in response to DNA damage [29,31,40].
Using antibodies against CHK2-phospho-Thr68 in im-
munofluorescence experiments (IF), Tsvetkov and col-
leagues reported that a subpopulation of CHK2 localizes
at centrosomes in interphase and mitotic cells in the ab-
sence of induced DNA damage [30]. In the same study, a
centrosomal localization for a subset of HA-tagged CHK2
protein under specific IF conditions with pre-extraction of
cells was reported [30]. The Thr383/387-phosphorylated
form of CHK2 has also been localized at centrosomes
in response to DNA damage, and CHK2 was found to
co-purify with centrosomes in gradient-purified centro-
some preparations [8,41]. Despite these observations, the
centrosomal localization of CHK2 remains controversial
and there are doubts regarding the specificity of the anti-
bodies used to demonstrate expression of CHK2 at the
centrosomes by immunofluorescence. In the present study
we show that anti-CHK2 antibodies used to stain CHK2 at
centrosomes cross-react non-specifically with an unknown
centrosomal protein(s). By using cells lines expressing Flag
or GFP-tagged CHK2 proteins, we demonstrate that
CHK2 localizes exclusively in the nucleus of cells in inter-
phase. However, we observed that a small portion of
CHK2 localizes to centrosomes in mitotic cells, from late
prophase until cytokinesis supporting a role for CHK2
during mitosis [15].
Results
CHK2 is localized in the nucleus but not at the
centrosomes in interphase cells
Several antibodies raised against CHK2 have been
reported to stain the centrosomes by immunofluores-
cence in HEK293T and U2OS cells [8,30]. We confirm
that both the rabbit polyclonal affinity-purified anti-
bodies raised against the N-terminal amino acids 1 to
300 of CHK2 (H-300) as well as the CHK2-phospho
-Thr68 antibody stain the centrosomes of U2OS cells
fixed with 100% methanol. To validate the specificity ofthese antibodies in immunofluorescence experiments, we
used an isogenic human colorectal cancer HCT116 cell
line with a targeted deletion of CHK2 [42]. The expected
62 kDa band corresponding to the molecular weight of
CHK2 protein was not detected in the HCT116 CHK2−/−
cells by Western blotting, but was detected in the wild
type (WT) cells (Figure 1A). Although we obtained posi-
tive staining at the centrosomes with the CHK2 H-300
and phospho-Thr68 antibodies in IF experiments there
was no significant difference in the staining at the centro-
somes between the HCT116 WT and CHK2 knockout
cells (Figure 1B). To confirm the results obtained with the
HCT116 cell lines, we generated human osteosarcoma
(U2OS) cell lines stably transduced with small hairpin
CHK2 RNAs targeting different regions of CHK2 ORF.
Lentiviral shRNAs directed against N-terminal sequences
of the CHK2 ORF located either at 3′ (shRNA-1) or 5′
(shRNA-2) of Thr68 were used to infect U2OS cells.
U2OS cells lines transduced with a CHK2 shRNA
targeting the 3′UTR sequence (shRNA-3) or with a com-
bination of shRNA 2 + 3 were also generated. We con-
firmed the shRNA-mediated silencing of CHK2 in the
stably transduced cells by immunoblotting, and noted that
the efficiency of CHK2 depletion varied between small
hairpins with shRNA-1 providing the best depletion
(Figure 2A). We then stained the cell lines generated
with the anti-CHK2 H-300 and phospho-Thr68 anti-
bodies. Although the intensity of staining with the
H-300 antibody in the U2OS cell lines depleted for
CHK2 decreased in the nucleus, the centrosomes
remained positively stained in all cell lines. There was
no significant decrease of the centrosomal signal in
CHK2-depleted cell lines compared to the untransduced
U2OS cells or cells transduced with control GFP-shRNAs
(Figure 2B-E). To validate the methodology we used to
quantify the fluorescence intensity signal at the centro-
somes, we generated a stable U2OS cell population
expressing a doxycycline-inducible GFP protein fused to
the PACT (pericentrin-AKAP450-centrosome targeting)
domain of AKAP450 [43]. Confirming previous reports,
we found that the GFP-PACT fusion protein localized
predominantly at the centrosomes (Figure 2F). We in-
duced the expression of the GFP-PACT fusion protein
by adding increasing doses of doxycycline to the culture
media. We observed a dose-dependent increase in the
expression of the GFP-PACT fusion protein that was
proportional to the intensity of the fluorescence mea-
sured at the centrosomes (Figure 2G and H). In sum-
mary, the staining pattern we obtained with the U2OS
cell lines is in agreement with that observed in the
HCT116 cells. We confirm that the CHK2 H-300 and
CHK2-phospho-Thr68 antibodies bind non-specifically
to protein(s) other than CHK2 localized at the centro-
somes in interphase cells.


























Figure 1 Centrosomes stain positive for CHK2 in human colon cancer cells deficient in CHK2. (A) There is no expression of CHK2 in
HCT116 CHK2−/− cells. HCT116 WT and HCT116 CHK2 knockout cells were subjected to Western blotting with anti-CHK2 antibody. (B) We did not
detect differences in the staining between WT and CHK2 knockout cells. Exponentially growing HCT116 WT and CHK2−/− cells were fixed and
immunostained with antibodies against the N-terminal portion of CHK2 (H-300) or the Thr68-phosphorylated form (P-Thr 68) (green). Cells were
costained for γ-tubulin (red) and counterstained with DAPI (blue).
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To examine more closely the localization of CHK2, we
generated stable U2OS cell lines that express the fusion
protein GFP-CHK2 or Flag-CHK2 under the control of
the doxycyclin-inducible promoter (Figure 3A). We first
assessed the functionality of the GFP and Flag-tagged
CHK2 proteins by examining their phosphorylation status
in response to DNA damage induced by ionizing radiation
(γ-IR). In response to gamma rays, the exogenous CHK2
fusion proteins were found phosphorylated on Thr 68,
Thr 383/387 and Ser 516 suggesting that the kinases are
fully active (see Additional file 1). In addition, we detected
an increase in the phosphorylation of the CHK2 substrate
CDC25 A (Ser 123) indicative of GFP- and Flag-CHK2
activation in the transduced cell lines relative to U2OS
control cells (see Additional file 1). These data suggest that
the doxycycline-inductible GFP-CHK2 and Flag-CHK2
proteins are functional kinases [2,3].
In direct immunofluorescence experiments performed
48 h following doxycycline addition to the culture
medium, we found GFP-CHK2 to be exclusively local-
ized in the nucleus of interphase cells with no apparent
centrosomal staining (Figure 3B). However, we detected
GFP-CHK2 at the centrosomes in mitotic cells. We
found a small subpopulation of GFP-CHK2 at the cen-
trosomes from the late prophase/early prometaphasestage, where centrosomes separate and migrate to cell
poles, until cytokinesis. We also observed GFP-CHK2
concentrated at the mid-body in late mitosis (Figure 3B).
Similar results were obtained in immunostained cells ex-
pressing Flag-CHK2 fusion protein (Figure 3C). The
centrosomal localization of GFP-CHK2 and Flag-CHK2
in mitotic cells was maintained when microtubules were
depolymerized by nocodazole treatment, suggesting that
CHK2 localizes to mitotic centrosomes in a microtubule-
independent manner (see Additional file 2). To further
control the reliability of these results, we also generated
U2OS cell lines transduced with the doxycycline-
inductible GFP, GFP-CHK1 and Flag-CHK1 constructs.
Unlike GFP-CHK2 and Flag-CHK2, the GFP, GFP-CHK1
and Flag-CHK1 proteins, although induced at high levels
in the U2OS cell lines, did not localize to the centrosomes
in mitotic cells (see Additional file 3). In interphase cells
expressing very high levels of GFP protein, some centro-
somes appeared slightly stained but most cells did not
stain at the centrosomes (see Additional file 3). Although
these results suggest that the centrosomal localization re-
vealed for GFP-CHK2 and Flag-CHK2 is specific, we
decided to further support our findings by performing
live-cell microscopy experiments. In living cells, we ob-
served that a fraction of GFP-CHK2 was associated with
the centrosomes during mitosis from early prometaphase



































































































































































































































































Figure 2 (See legend on next page.)
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Figure 2 Centrosomal staining for CHK2 antibodies persists in cells expressing CHK2 targeting shRNAs. U2OS cells were stably transduced
with various shRNAs directed against CHK2 or GFP. (A) Western blots showing the expression level of endogenous CHK2 in the transduced cell lines.
(B and D) Cells were fixed and immunostained with the indicated anti-CHK2 antibodies (green) and costained for centrosomes (red) and DNA (blue).
Representative fields of the immunofluorescence stainings obtained with the indicated cell lines are shown. (C and E) The fluorescence intensity of the
CHK2 antibodies H-300 and P-Thr 68 was quantified and represented as a ratio of the control γ-tubulin signal at centrosomes. This ratio was set at
100% in control untransduced cells. Results are representative of 3 independent experiments where the intensity at the centrosomes was monitored
in 200 cells. Error bars represent the standard deviation from the mean of 3 experiments. To validate the method of quantification of the fluorescence
intensity signal at centrosomes, stable transduced GFP-PACT U2OS cells were generated. (F) A representative field showing the centrosomal
localization of the GFP-PACT fusion protein. 48 h after 20 ng/ml doxycycline addition, cells were fixed and stained with anti-γ-tubulin antibody (red)
and DAPI (blue). GFP-PACT was visualized by direct fluorescence. (G, H) GFP-PACT expression was induced with 2.5, 5 or 20 ng/ml doxycycline and
cells were stained as in (F). (G) The expression of GFP-PACT at each doxycycline concentration was analyzed by Western blotting using anti-GFP
antibody. The arrow indicates the bands corresponding to GFP-PACT and the asterisk designates non-specific signal. (H) The fluorescence intensity at
centrosomes of GFP-PACT was quantified as in C and E and set at 100% in cells induced with 20 ng/ml doxycycline. Graphs represent the mean of
intensity ± s.d. of 3 independent experiments.
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the bipolar mitotic spindle. In contrast to GFP-CHK2, no
specific enrichment of GFP at any particular structure was
detected in mitotic cells (Figure 4 and Additional movie
files 4 and 5). Collectively, our results indicate that a sub-
population of CHK2 localizes at centrosomes specifically
in mitotic cells. These data are consistent with the novel
function proposed for CHK2 in the mitotic spindle assem-
bly and the progression of mitosis reported recently by
others [15].
Polo kinase 1 is required for CHK2 localization at
centrosomes
Polo-like kinase 1 (PLK1) is a key mitotic kinase that
regulates mitotic entry and mitosis progression. PLK1
localizes to centrosomes and kinetochores in early mi-
totic stages and at the central spindle and mid-body in
anaphase and cytokinesis [44,45]. Since PLK1 localizes at
the centrosomes and regulates CDK1-Cyclin B activa-
tion, centrosome maturation and separation as well as
spindle assembly, we examined whether it is required for
the recruitment of CHK2 at mitotic centrosomes. U2OS
cells induced for GFP-CHK2 expression were treated
with BI 2536 an inhibitor of PLK1, or monastrol an in-
hibitor of the Eg5 kinesin [46-48]. We found that both
treatments inhibit centrosomes separation resulting in
the formation of monopolar spindles and the arrest of
cells in prometaphase (Figure 5A). In cells treated with
monastrol, GFP-CHK2 was present at the unseparated
centrosomes of the monopoles while it was not associated
with centrosomes in BI 2536-treated cells, suggesting that
PLK1 kinase activity is required for CHK2 recruitment
at the centrosome during mitosis. To confirm the role
of PLK1 in targeting CHK2 at the centrosome, we de-
pleted the expression of PLK1 using short interfering
RNA (siRNA).
Unlike BI 2536 that strongly inhibits centrosome sep-
aration, cells transfected with siRNA against PLK1
arrested at late prophase/early prometaphase withunseparated centrosomes or at metaphase showing effect-
ive centrosome separation (Figure 5B and Additional file
6). Accumulation of these cells in metaphase most likely
results from the incomplete silencing of PLK1 by the
siRNA, as observed on the Western blots (Figure 5C and
Additional file 6B). Alternatively, a potential off-target ef-
fect of BI 2536 is also possible [46]. In addition, PLK1
silencing or inhibition has no effect on centrosomes in
interphase (Additional file 7). Most importantly, in all
mitotic-arrested cells following siRNA-mediated PLK1 de-
pletion or inhibition, the association of GFP-CHK2 with
centrosomes was inhibited suggesting that PLK1 activity is
required for CHK2 recruitment at the centrosomes during
mitosis. However, data presented in Additional files 6 and
7 indicate that CHK2 silencing does not influence centro-
some duplication and separation.
Discussion
Increasing evidence indicates that centrosomes integrate
pathways that regulate cell cycle progression in interphase
and mitosis. In the past years, key proteins of the DNA
damage response have been localized at the centrosomes
supporting a role for DNA damage responsive molecules
in the control of unperturbed cell cycle progression and
mitosis. Several studies revealed a centrosomal
localization for CHK2 in interphase and mitotic cells
[30,31,41]. We show here that the CHK2 rabbit poly-
clonal antibodies H-300 and CHK2-phospho-Thr68
stain the centrosomes by cross-reacting with an un-
known centrosomal protein(s). By using U2OS cells
transfected with Flag and GFP-tagged CHK2 fusion pro-
teins we demonstrate that a subpopulation of CHK2
localizes at the centrosomes specifically in mitotic cells,
from the late prophase/early prometaphase stage until
cytokinesis. Moreover, we show that the centrosomal
localization of CHK2 depends on PLK1 activity.
Our finding is in agreement with a recent work pub-
lished by Stolz and al., supporting a new function for
CHK2 in the mitotic bipolar spindle assembly and the







































































Figure 3 (See legend on next page.)
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Figure 3 CHK2 localizes at centrosomes in mitotic cells but not in interphase. U2OS cells were transduced with lentiviruses coding for GFP-
CHK2 or Flag-CHK2 and stably selected. (A) Cells were exposed for 48 h to doxycycline at 5 ng/ml for GFP-CHK2 cells, or 20 ng/ml for Flag-CHK2
cells, and expression of proteins in whole cell extracts was analyzed by Western blotting using the indicated antibodies. The arrows indicate
endogenous and exogenous CHK2 proteins. Note that some exogenous CHK2 is expressed without tag. β-actin was used as loading control.
(B and C) GFP-CHK2 and Flag-CHK2 are exclusively localized in the nucleus of interphase cells whereas a small subpopulation localizes at the
centrosomes during mitosis. 48 h following transgene induction cells were fixed in methanol. Centrosomes were stained with anti-γ-tubulin
antibody (red), and DNA was counterstained with DAPI (blue). The localization of GFP-CHK2 was observed by direct fluorescence and Flag-CHK2
was immunostained with an anti-Flag antibody (green). Cells in interphase and various phases of mitosis were selected.
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colon cancer cell line HCT116 [15]. In this study, the
tumor suppressor BRCA1 has been identified as a mi-
totic target of CHK2, and alteration of the CHK2-
BRCA1 pathway was shown to promote chromosomes
segregation errors in dividing cells, a feature that is com-
monly observed in cancer cells and might drive chromo-
somal instability and cellular transformation [15,49,50].
Whether this new function of CHK2 in mitosis is associ-
ated with the centrosomal pool of CHK2 remains to be
established. Interestingly, the CHK2 substrate BRCA1 has
also been localized at the centrosomes in mitotic cells
where it was reported to inhibit microtubule nucleation,
an event that initiates entry into mitosis [26,51-54].
The kinase CHK2 is a checkpoint kinase known for its
functions in the DNA damage response and is detected in
the nucleus of interphase cells. In response to DNA damage
CHK2 phosphorylates several targets in vivo including
the phosphatases CDC25 A and C, the tumor suppressor
BRCA1, the promyelocytic leukemia protein (PML), as well
as the transcription factors p53, E2F1 and FOXM1 whichGFP-CHK2
GFP
Figure 4 GFP-CHK2 localizes at centrosomes and spindle in mitotic liv
mitotic U2OS cells expressing GFP-CHK2 or GFP proteins. Arrowheads indicare all involved in cell cycle checkpoints, programmed cell
death and DNA repair [55-60]. More recently, CHK2 has
been demonstrated to be required for the proper progres-
sion of mitosis in HCT116 cells [15]. Interestingly, recent
findings indicate that several other key proteins of the
DNA damage response, including CHK1, ATM, DNA-PK,
MDC1 and BRCA2 also play roles in regulating the proper
progression of mitosis and/or the mitotic spindle assembly
checkpoint (SAC), supporting the existence of a functional
crosstalk between proteins of the DNA damage response
and the mitotic regulatory network [8-13,22,61-66].Conclusion
Despite several recent reports documenting the pres-
ence of CHK2 at centrosomes there was some doubt
about the specificity of the antibodies that stained
positively for CHK2 at the centrosomes by immuno-
fluorescence. In this study we conclusively show that
CHK2 does not localize at the centrosomes in inter-
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Figure 5 Polo kinase 1 is required for CHK2 localization at centrosomes. (A) Inhibition of PLK1 activity with BI 2536 inhibits GFP-CHK2
association with centrosomes. U2OS GFP-CHK2 cells were incubated with doxycycline at 5 ng/ml for 32 h and treated for an additional 16 h with
BI 2536 (100 nM) or monastrol (100 μM) in doxycycline-containing medium. Cells were then fixed and stained for centrosomes (red) and DNA
(blue) and GFP-CHK2 was visualized by direct fluorescence (green). (B) Inhibition of PLK1 expression prevents GFP-CHK2 association with
centrosomes during mitosis. U2OS GFP-CHK2 cells were transfected with a siRNA directed against PLK1 or control siRNA. 48 h post-transfection
cells were fixed to examine GFP-CHK2 localization by fluorescence microscopy as in (A). (C) Western blot analysis of PLK1 expression shows a
significant decrease in the expression of PLK1. Cell lysate from PLK1 siRNA-transfected U2OS cells was prepared from arrested mitotic cells
collected by shake-off 48 h post-transfection. As a control, U2OS cells transfected with control siRNA were synchronized in mitosis by a 16 hours
nocodazole block and protein extracts were prepared from the mitotic cells collected by shake-off.
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manner during mitosis.
Methods
Cells culture and reagents
Human osteosarcoma U2OS cells used in all experiments
stably express the tetracycline (Tet) repressor. U2OS T-
REx cells were obtained from Dr. Eric Campeau(University of Massachusetts, USA). HCT116 WT and
CHK2−/− cells were a gift from Dr. Fred Bunz (Johns
Hopkins University, Baltimore, USA) to Dr. Francis Rodier.
Cells were maintained at 37°C, 5% CO2 in Dulbecco’s
modified Eagle’s Medium supplemented with 10% fetal calf
serum. BI 2536 (Axon Medchem) and monastrol (Enzo
Life sciences) were used at 100 nM and 100 μM respect-
ively. Nocodazole was purchased from Sigma-Aldrich.
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To generate inducible U2OS cells lines expressing
CHK2 or CHK1 fused to the GFP or FLAG tag, CHK1
and CHK2 cDNAs were cloned into the entry vectors
pENTR4-GFP-C3 (Addgene # w393-1) and pENTR4-
FLAG (Addgene # w210-2) respectively and the entry
vectors were recombined into the inducible destination
vector pLenti CMV/TO Puro (Addgene # 670–1). To
generate inducible U2OS cells expressing GFP-PACT fu-
sion protein, the PACT domain (amino acids 3643–
3808) of AKAP450 was amplified from the GFP-
AKAP450 vector provided by Dr. S. Munro (Cambridge,
United Kingdom) with the following primers: forward,
5′-AAGCTTGCCAACATTGAAGCCATCATTGCC-3′
and reverse, 5′-GAATTCTTATGCACCTTGATTCAG
TCCAAAGC-3′. The amplified sequence was cloned
into the entry vector pENTR4-GFP-C3 (Addgene #
w393-1) that was recombined into the destination vector
pLenti CMV/TO Puro (Addgene # 670–1). Lentiviruses
for all the constructs were generated with virus titers to
infect 50 to 80% of cells and stably transduced cells were
selected with 0.5 microgram /ml puromycin [67].
RNA interference
RNAi lentiviruses previously shown to effectively reduce
CHK2 levels were purchased from Open Biosystems
[68]. The short hairpin target sequences used were:






For PLK1 knockdown, cells were transfected with a
siRNA targeting the sequence 5′-AGAUUGUGCCUAA
GUCUCU-3′ [69,70]. Transfection of siRNAs was car-
ried out using DharmaFECT reagent (Thermo Scientific,
Dharmacon) according to manufacturer’s instructions.
Immunofluorescence microscopy
Cells were grown on high precision 18 mm/1.5H glass cov-
erslips (Marienfeld) and fixed in −20°C methanol for
15 min and blocked with PBS containing 3% BSA, 2% FCS,
0.3% Triton X-100. Fixed cells were incubated for 1 hour
at room temperature with the indicated primary antibodies
diluted in blocking buffer, and for 45 min with the Alexa
Fluor-conjugated secondary antibodies. DNA was stained
for 5 min with DAPI at 100 ng/ml (Sigma). Images were
acquired using a Nikon Eclipse 600 fluorescence micro-
scope equipped with a CoolSNAP HQ2 camera (Photomet-
rics) and processed using NIS-Element AR 3.0 and
Photoshop (CS5, Adobe). Cells were immunostained using
the following primary antibodies: anti-γ-tubulin (GTU-88,
Sigma T6557, 1:2000), anti-CHK2 (H300, Santa Cruz,1:50), anti-phospho-Thr68-CHK2 (Cell signaling 1:50),
anti-α-tubulin (DM1A, Sigma 1:500), anti-Flag (M2, Sigma,
1:1000), anti-Flag (F7425, Sigma, 1:250), anti-PLK1 (#06-
813, Millipore 1:100) and the secondary antibodies Alexa
Fluor 488/TxRed (Molecular Probes, 1: 800). For the quan-
tification of fluorescence signal intensities at the centro-
somes, unsaturated images were acquired with the same
exposure settings. The areas corresponding to the centro-
somes were defined with the γ-tubulin stainings and fluor-
escence intensities within the determined centrosomal
areas were measured using NIS-Element software.Western blotting
To prepare protein extracts, cells were lysed in lysis buffer
containing 50 mM Tris–HCl pH 7.4, 150 mM NaCl, 1%
Triton X-100, 2.5 mM Na3VO4, 10 mM NaF, 5 mM so-
dium pyrophosphate, 2 mM phenylmethylsulfonyl fluoride
(PMSF), 10 μM MG132, 20 mM β-glycerophosphate, and
a cocktail of proteases inhibitors (Complete™ Roche Ap-
plied Science). Proteins were run on 10% SDS-PAGE gels,
transferred on nitrocellulose membranes and analyzed by
immunoblotting. The antibodies used were anti-GFP
(ab290, abcam, 1:1000), anti-Flag (M2, Sigma, 1:1000),
anti-CHK2 (B-4, Santa Cruz, 1:500), anti-CHK1 (DCS-
310, SantaCruz 1:500), anti-phospho-Thr68-CHK2 (Cell
signalling, 1:1000), anti-phospho-Thr387-CHK2 (Assay
bioTech, 1:500), anti-phospho-Ser516-CHK2 (Cell signal-
ling, 1:1000), anti-phospho-Ser123-CDC25A (MJS Biolynx
1:250), anti-PLK1 (#06-813, Millipore, 1:500) and anti-β
-actin (AC-74, Sigma, 1:20 000).Time-lapse microscopy
For live cell videomicroscopy, U2OS cells transduced
with GFP-CHK2WT or control GFP were grown on
CellView™ 35 mm glass bottom dishes (170 ± 10 μM bot-
tom thickness) from Greiner-Bio One. Protein expression
was induced by a 48 h doxycycline treatment and cells
were synchronized at the G1/S transition using a single
24 h thymidine block. 8 h after release from thymidine
block they were incubated in FCS-supplemented, phenol
red-free Dulbecco’s modified Eagle’s Medium and placed
at 37°C in a heated chamber maintained at 5% CO2. Im-
ages were collected on a Zeiss Axio Observer Z1 auto-
mated microscope every 2.5 minutes for 16 hours using a
Plan-Apochromat 20x/0.8NA objective, a Zeiss HRm
Axiocam and LED pulsed light illumination setup.Statistical analysis
Statistical analyses were performed using a two-tailed
Student t-test, type 3. Difference with P < 0.05 is consid-
ered as significant.
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Additional file 1: The exogenous GFP-CHK2 and Flag-CHK2 fusion
proteins are functional kinases. U2OS GFP-CHK2 and U2OS Flag-CHK2
cell lines were incubated with doxycycline for 48 h to induce transgene
expression and cells were exposed to γ-IR (10 Gy ). (A) 1 h after
genotoxic insult whole-cell lysates were prepared and phosphorylation of
CHK2 fusion proteins on Thr 68, Thr 383/387 and Ser 516 was assessed
by Western blotting using the indicated antibodies. The arrows indicate
GFP-CHK2 and Flag-CHK2 proteins phoshorylated on Thr383/387. (B) The
phosphorylation of the CHK2 substrate CDC25 A (Ser123) was analyzed
by Western blotting of protein extracts prepared 8 h after irradiation. The
arrow indicates the band corresponding to P-Ser123-CDC25A. Both GFP-
CHK2 and Flag-CHK2 retain full kinase activity.
Additional file 2: During mitosis the localization of CHK2 at the
centrosomes is microtubules independent. Doxycycline-induced U2OS
GFP-CHK2 and U2OS Flag-CHK2 cell lines were incubated for 16 h in
nocodazole (0.3 μM) to arrest cells in prometaphase. Cells were treated
for an additional hour with 10 μM nocodazole prior to be fixed and
stained with anti-γ-tubulin antibody (red) to stain the centrosomes. GFP-
CHK2 was visualized by direct fluorescence and Flag-CHK2 was
immunostained with an anti-Flag antibody (green). To control
microtubules depolymerization cells were also stained for α-tubulin.
Additional file 3: GFP, GFP-CHK1 and Flag-CHK1 do not localize to
the centrosomes. U2OS stably transduced with lentiviruses coding for
GFP, GFP-CHK1 or Flag-CHK1 were exposed to doxycycline at 5 ng/ml,
10 ng/ml and 20 ng/ml. (A) 48 h following doxycycline addition cells
were collected. The expression of exogenous proteins was analyzed by
Western blotting using the indicated antibodies. The arrows denote
endogenous and exogenous CHK1 proteins. β-actin was used as loading
control. (B-D) 48 h post-induction, cells were fixed and immunostained
with anti-γ-tubulin antibody (red) and costained with DAPI (blue). The
localization of GFP and GFP-CHK1 was observed by direct fluorescence
and Flag-CHK1 was immunostained with an anti-Flag antibody (green).
Cells in interphase and various phases of mitosis were selected.
Additional file 4: Time-lapse movie showing GFP-CHK2 at
centrosomes in mitotic U2OS cells. U2OS GFP-CHK2 were incubated
with doxycycline for 48 h and synchronized by a single 24 h thymidine
block. When the synchronized cell population progressed through late
G2 phase and mitosis, images were acquired every 2 minutes with a
Zeiss Axio Observer Z1 automated microscope.
Additional file 5: Time-lapse movie showing a mitotic U2OS cell
expressing control GFP protein. Cells were imaged in the same
conditions as for Additional file 4.
Additional file 6: Quantification of centrosome separation in
mitotic cells. (A) Control U2OS cells or cells stably transduced with CHK2
shRNA 1 or CHK2 shRNA 2 + 3 were transfected with a siRNA directed
against PLK1 or incubated with BI 2536 (100 nM). 24 h following
transfection or 16 h after treatment with BI 2536, cells were fixed and
stained with anti-γ-tubulin antibody and DAPI. Representative images of
the mitotic-arrested cells are shown. The percentage of each mitotic
cellular population was measured. Error bars represent the mean ± s.d. of
3 independent experiments, each experiment monitoring 200 mitotic
cells (*P < 0.05; _ P > 0,05). (B) Western blot analysis of PLK1 expression.
Cell lysates from PLK1 siRNA-transfected U2OS cells were prepared from
mitotic cells collected by shake-off 24 h post-transfection. Protein extracts
prepared from asynchronous cells or mitotic cells collected by shake-off
24 h following nocodazole treatment serves as control.
Additional file 7: Quantification of centrosomes duplication/
separation in interphase. (A) Experimental procedure. Control U2OS
cells or cells stably transduced with CHK2 shRNA 1 were synchronized at
the G1/S boundary by a double thymidine block (DTB). At the indicated
times during the cell cycle synchronization protocol, cells were
transfected with control or PLK1 siRNAs, incubated with BI 2536 or left
untreated. (B) After release from second thymidine block, cell
synchronization was confirmed by FACS analysis at the indicated times.
(C) The inhibition of PLK1 expression was confirmed by Western blotting.
Cell lysates from PLK1 siRNA-transfected cells were prepared from mitoticcells collected by shake-off 11,5 h after release from DTB. Protein extracts
prepared from mitotic cells collected 24 h following nocodazole
treatment serves as control. (D) At each time point after release, cells
were fixed and stained with anti-γ-tubulin antibody and DAPI. The
interphase cells with one or two unseparated/separated centrosomes
were divided in 4 patterns, as shown in representative images, and cells
in each pattern were quantified. Error bars represent the mean ± s.d.
of 3 independent experiments, each experiment monitoring 200
interphase cells.
Abbrevations
IF: Immunofluorescence; ORF: Open reading frame; γ-IR: Gamma-irradiation;
PLK1: Polo-like kinase 1.
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